首页> 美国卫生研究院文献>PLoS Clinical Trials >In Silico Structural and Functional Characterization of the RSUME Splice Variants
【2h】

In Silico Structural and Functional Characterization of the RSUME Splice Variants

机译:RSUME拼接变体的计算机模拟结构和功能表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

RSUME (RWD-containing SUMO Enhancer) is a small protein that increases SUMO conjugation to proteins. To date, four splice variants that codify three RSUME isoforms have been described, which differ in their C-terminal end. Comparing the structure of the RSUME isoforms we found that, in addition to the previously described RWD domain in the N-terminal, all these RSUME variants also contain an intermediate domain. Only the longest RSUME isoform presents a C-terminal domain that is absent in the others. Given these differences, we used the shortest and longest RSUME variants for comparative studies. We found that the C-terminal domain is dispensable for the SUMO-conjugation enhancer properties of RSUME. We also demonstrate that these two RSUME variants are equally induced by hypoxia. The NF-κB signaling pathway is inhibited and the HIF-1 pathway is increased more efficiently by the longest RSUME, by means of a greater physical interaction of RSUME267 with the target proteins. In addition, the mRNA and protein levels of these isoforms differ in human glioma samples; while the shortest RSUME isoform is expressed in all the tumors analyzed, the longest variant is expressed in most but not all of them. The results presented here show a degree of redundancy of the RSUME variants on the SUMO pathway. However, the increased inhibition conferred by RSUME267 over the NF-κB signaling pathway, the increased activation over the HIF-1 pathway and the different expression of the RSUME isoforms suggest specific roles for each RSUME isoform which may be relevant in certain types of brain tumors that express RSUME, like human pituitary adenomas and gliomas.
机译:RSUME(含RWD的SUMO增强剂)是一种小的蛋白质,可增加SUMO与蛋白质的结合。迄今为止,已经描述了编码三个RSUME同工型的四个剪接变体,它们的C末端不同。比较RSUME同工型的结构,我们发现,除了先前描述的N末端的RWD结构域之外,所有这些RSUME变体还包含一个中间结构域。只有最长的RSUME同工型具有一个C末端域,而其他末端不存在。考虑到这些差异,我们将最短和最长的RSUME变体用于比较研究。我们发现,C末端域对于RSUME的SUMO缀合增强子特性是可有可无的。我们还证明了这两个RSUME变体同样被缺氧诱导。通过最长的RSUME,通过RSUME267与靶蛋白的更大的物理相互作用,可以抑制NF-κB信号通路,并更有效地增加HIF-1通路。此外,在人类神经胶质瘤样品中,这些同工型的mRNA和蛋白质水平也有所不同。尽管在分析的所有肿瘤中都表达了最短的RSUME同工型,但在大多数但并非全部中都表达了最长的变异体。此处显示的结果显示了SUMO途径中RSUME变体的冗余程度。但是,RSUME267对NF-κB信号通路的抑制作用增加,HIF-1通路的活化作用增加以及RSUME亚型的不同表达,提示每种RSUME亚型的特定作用可能与某些类型的脑肿瘤有关像人类垂体腺瘤和神经胶质瘤一样表达RSUME。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号